Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer | 5739 | 1491144-00-3 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Avacincaptad pegol is an RNA aptamer, a PEGylated oligonucleotide that binds to and inhibits complement protein C5. By inhibiting C5, avacincaptad pegol may prevent its cleavage to C5a and C5b thus decreasing membrane attack complex (MAC) formation.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 4, 2023 | FDA | IVERIC BIO |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | S01XA32 | SENSORY ORGANS OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS Other ophthalmologicals |
| FDA EPC | N0000175575 | Complement Inhibitor |
| MeSH PA | D007155 | Immunologic Factors |
| MeSH PA | D007166 | Immunosuppressive Agents |
| MeSH PA | D051056 | Complement Inactivating Agents |
| FDA MoA | N0000175974 | Complement Inhibitors |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Geographic atrophy secondary to age-related macular degeneration | indication | 414875008 | |
| Uveitis | contraindication | 128473001 | DOID:13141 |
| Ocular or periocular infection | contraindication | 715266002 |
None
None
None
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) | IZERVAY | ASTELLAS | N217225 | Aug. 4, 2023 | RX | SOLUTION | INTRAVITREAL | 8236773 | Nov. 11, 2026 | TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE |
| EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) | IZERVAY | ASTELLAS | N217225 | Aug. 4, 2023 | RX | SOLUTION | INTRAVITREAL | 9617546 | Feb. 14, 2027 | TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE |
| EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) | IZERVAY | ASTELLAS | N217225 | Aug. 4, 2023 | RX | SOLUTION | INTRAVITREAL | 11273171 | July 11, 2034 | TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE |
| EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) | IZERVAY | ASTELLAS | N217225 | Aug. 4, 2023 | RX | SOLUTION | INTRAVITREAL | 11491176 | July 11, 2034 | TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE |
| EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML) | IZERVAY | ASTELLAS | N217225 | Aug. 4, 2023 | RX | SOLUTION | INTRAVITREAL | 12016875 | July 11, 2034 | TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE |
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Complement C5 | Secreted | INHIBITOR | Kd | 9.85 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| 1613641-69-2 | SECONDARY_CAS_RN |
| CHEBI:760479 | CHEBI |
| CHEMBL6068573 | ChEMBL_ID |
| C000731678 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12857 | IUPHAR_LIGAND_ID |
| DB15165 | DRUGBANK_ID |
| 4042480 | VANDF |
| C5139850 | UMLSCUI |
| CHEMBL4297889 | ChEMBL_ID |
| 10099 | INN_ID |
| 370101 | MMSL |
| 41876 | MMSL |
| 019514 | NDDF |
| 019515 | NDDF |
| D11748 | KEGG_DRUG |
| TT0V5JLG5B | UNII |
| 2645107 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| IZERVAY | HUMAN PRESCRIPTION DRUG LABEL | 1 | 82829-002 | INJECTION | 20 mg | INTRAVITREAL | NDA | 26 sections |